Ann: Expanded Heart Protection Discovery for Zantrene, page-184

The announced plan is that bisatrene will first be approved as a single agent for EMD AML. That was announced long before the recent cardioprotection findings.
If there's a change in plan, it hasn't been announced.
I guess RAC will proceed as already announced because the 505(b)(2) pathway is the fastest route to approval.

As for administering two drugs separately rather than coformulated, I have no idea whether the coformulation has advantages other than convenience and avoiding errors. I have zero medical background.

==================

There's no way to edit previous HC posts later than about 30 seconds from having posting them.